anit abcb1 Search Results


anit abcb1  (Proteintech)
96
Proteintech anit abcb1
Effect of PF on the expression of CYP2C9, <t>ABCB1,</t> MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.
Anit Abcb1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anit+abcb1/pmc08435635-102-38-35?v=Proteintech
Average 96 stars, based on 1 article reviews
anit abcb1 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anit abcb1  (Boster Bio)
92
Boster Bio anit abcb1
Effect of PF on the expression of CYP2C9, <t>ABCB1,</t> MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.
Anit Abcb1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anit+abcb1/pmc08435635-102-38-40?v=Boster+Bio
Average 92 stars, based on 1 article reviews
anit abcb1 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
mdr1/abcb1 antibody (mrk16) [allophycocyanin] - chimeric  (Novus Biologicals)
N/A
The MDR1/ABCB1 Antibody (MRK16) [Allophycocyanin] - Chimeric from Novus is a MDR1/ABCB1 antibody to MDR1/ABCB1. This antibody reacts with Human. The MDR1/ABCB1 antibody has been validated for the following applications: Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation,
   Buy from Supplier
mdr1/abcb1 antibody (mdr1/8986r) [allophycocyanin]  (Novus Biologicals)
N/A
The MDR1/ABCB1 Antibody (MDR1/8986R) [Allophycocyanin] from Novus is a MDR1/ABCB1 antibody to MDR1/ABCB1. This antibody reacts with Human. The MDR1/ABCB1 antibody has been validated for the following applications: Immunohistochemistry-Paraffin.
   Buy from Supplier
abcb11 antibody (bsep/7534) [allophycocyanin]  (Novus Biologicals)
N/A
ABCB11 Antibody (BSEP/7534) [Allophycocyanin]
   Buy from Supplier
mdr1/abcb1 antibody (mrk16) [allophycocyanin]  (Novus Biologicals)
N/A
The MDR1/ABCB1 Antibody (MRK16) [Allophycocyanin] from Novus is a MDR1/ABCB1 antibody to MDR1/ABCB1. This antibody reacts with Human. The MDR1/ABCB1 antibody has been validated for the following applications: Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, CyTOF-ready.
   Buy from Supplier
mdr1/abcb1 antibody (mdr1/8962r) [allophycocyanin]  (Novus Biologicals)
N/A
The MDR1/ABCB1 Antibody (MDR1/8962R) [Allophycocyanin] from Novus is a MDR1/ABCB1 antibody to MDR1/ABCB1. This antibody reacts with Human. The MDR1/ABCB1 antibody has been validated for the following applications: Immunohistochemistry-Paraffin.
   Buy from Supplier

Image Search Results


Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Journal: Frontiers in Pharmacology

Article Title: Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology

doi: 10.3389/fphar.2021.737630

Figure Lengend Snippet: Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Article Snippet: The PVDF membranes were blocked with 5% fat-free milk at room temperature for 2 hours, then incubated overnight at 4°C with antibodies against anit-CDC25B (PB9488, BOSTER, dilution: 1:1,000), anit-MTOR (A00003-2, BOSTER, dilution: 1:1,000), anit-CYP2C9 (16546-1-AP, proteintech, dilution: 1:2,000), anit-ABCB1 (A00049-3, BOSTER, dilution: 1:1,000), anit-MAOB (PB9665, BOSTER, dilution: 1:1,000).

Techniques: Expressing, Western Blot

Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury. (A) The expression of CYP2C9 in the liver tissue; (B) The expression of ABCB1 in the liver tissue; (C) The expression of MAOB in the liver tissue; (D) The expression of CDC25B in the liver tissue; (E) The expression of MTOR in the liver tissue. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Journal: Frontiers in Pharmacology

Article Title: Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology

doi: 10.3389/fphar.2021.737630

Figure Lengend Snippet: Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury. (A) The expression of CYP2C9 in the liver tissue; (B) The expression of ABCB1 in the liver tissue; (C) The expression of MAOB in the liver tissue; (D) The expression of CDC25B in the liver tissue; (E) The expression of MTOR in the liver tissue. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Article Snippet: The PVDF membranes were blocked with 5% fat-free milk at room temperature for 2 hours, then incubated overnight at 4°C with antibodies against anit-CDC25B (PB9488, BOSTER, dilution: 1:1,000), anit-MTOR (A00003-2, BOSTER, dilution: 1:1,000), anit-CYP2C9 (16546-1-AP, proteintech, dilution: 1:2,000), anit-ABCB1 (A00049-3, BOSTER, dilution: 1:1,000), anit-MAOB (PB9665, BOSTER, dilution: 1:1,000).

Techniques: Expressing

Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Journal: Frontiers in Pharmacology

Article Title: Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology

doi: 10.3389/fphar.2021.737630

Figure Lengend Snippet: Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury detected by western blotting. (A) Western blotting images of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR; (B) Relative protein expression of CDC25B; (C) Relative protein expression of CYP2C9; (D) Relative protein expression of MAOB; (E) Relative protein expression of ABCB1; (F) Relative protein expression of MTOR. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Article Snippet: The PVDF membranes were blocked with 5% fat-free milk at room temperature for 2 hours, then incubated overnight at 4°C with antibodies against anit-CDC25B (PB9488, BOSTER, dilution: 1:1,000), anit-MTOR (A00003-2, BOSTER, dilution: 1:1,000), anit-CYP2C9 (16546-1-AP, proteintech, dilution: 1:2,000), anit-ABCB1 (A00049-3, BOSTER, dilution: 1:1,000), anit-MAOB (PB9665, BOSTER, dilution: 1:1,000).

Techniques: Expressing, Western Blot, Control

Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury. (A) The expression of CYP2C9 in the liver tissue; (B) The expression of ABCB1 in the liver tissue; (C) The expression of MAOB in the liver tissue; (D) The expression of CDC25B in the liver tissue; (E) The expression of MTOR in the liver tissue. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Journal: Frontiers in Pharmacology

Article Title: Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology

doi: 10.3389/fphar.2021.737630

Figure Lengend Snippet: Effect of PF on the expression of CYP2C9, ABCB1, MAOB, CDC25B, and MTOR in the treatment of cholestatic liver injury. (A) The expression of CYP2C9 in the liver tissue; (B) The expression of ABCB1 in the liver tissue; (C) The expression of MAOB in the liver tissue; (D) The expression of CDC25B in the liver tissue; (E) The expression of MTOR in the liver tissue. The data are expressed as the mean ± SD, n = 3. ## p < 0.01, # p < 0.05 compared with the control group, ** p < 0.01, * p < 0.05 compared with ANIT group.

Article Snippet: The PVDF membranes were blocked with 5% fat-free milk at room temperature for 2 hours, then incubated overnight at 4°C with antibodies against anit-CDC25B (PB9488, BOSTER, dilution: 1:1,000), anit-MTOR (A00003-2, BOSTER, dilution: 1:1,000), anit-CYP2C9 (16546-1-AP, proteintech, dilution: 1:2,000), anit-ABCB1 (A00049-3, BOSTER, dilution: 1:1,000), anit-MAOB (PB9665, BOSTER, dilution: 1:1,000).

Techniques: Expressing, Control